Biocon Ltd.

Biocon Limited, India’s largest fully integrated, innovation-led biopharmaceutical company based in Bengaluru, specialises in the treatment of diabetes, cancer, and autoimmune diseases. Biocon was incorporated in 1978. Its business segments encompass Generics, Biosimilars, Novel Biologics, and Research Services.

It has developed and commercialised novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and numerous global markets. Additionally, its Generic Formulations serve the United States, Europe, and key emerging markets.

Its API portfolio covers cardiovascular, anti-diabetics, immunosuppressants, multiple sclerosis, anti-fungal and other key products. The products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others.

It has over five R&D and manufacturing facilities across Bangalore, Hyderabad and Visakhapatnam in India. The API manufacturing facilities leverage its complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.

The company’s subsidiaries include Biocon Academy in India, Biocon Pharma Limited in India, Biocon Biologics Limited in India, Biocon FZ LLC in the UAE, and several others.